News

Year: 
2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001
12/21/2009 Paul Capital Healthcare Leads $100+ Million Investment with UCB
12/9/2009 Pharming Confirms Interaction With US FDA For Rhucin
11/2/2009 Flutiform EU Clinical Trial Successfully Completed
10/23/2009 Orthovita Announces Presentation of Cortoss Clinical Study Results at the 2009 Congress of Neurological Surgeons Annual Meeting
10/22/2009 Catalysts in the Development of Emerging Markets Private Equity
10/20/2009 On-X Life Technologies Completes Enrollment in High-Risk Patient Group of Low-Anticoagulation Trial
9/23/2009 Pharming’s Marketing Authorisation Application For Rhucin Validated By The European Medicines Agency (EMEA)
9/14/2009 Surprise Moves In Secondaries Chess Game
9/8/2009 Huge Surge in Demand for Private Equity Bargains
9/3/2009 Pharming Submits Marketing Authorisation Application For Rhucin® To The EMEA
8/17/2009 Asian PE Secondary Market Promising
8/4/2009 Paul Capital Bolsters Global Team
7/31/2009 Big banks are prime sellers of private equity
7/29/2009 Clinical Update – PSD502 for Premature Ejaculation
7/1/2009 Pharming Confirms Positive Results From Final Analysis Of Rhucin® Studies
6/4/2009 Pharming Receives Agreement On Paediatric Investigation Plan For Rhucin® From The EMEA Paediatric Committee
6/2/2009 Orthovita Announces Upcoming VITOSS Bone Graft Substitute Presentations Scheduled for the 2009 American College of Spine Surgery Annual Meeting and the 2009 Global Spine Congress
6/1/2009 Firms Wait to Harvest Secondaries
6/1/2009 Interim Analysis Confirms Immunosafety Of Rhucin®
5/26/2009 Global Agreement for PSD502, Financial Restructuring and 2008 Preliminary Results
5/22/2009 Flutiform NDA Accepted for Review
5/15/2009 Paul Capital Healthcare to Participate in Panel on Non-Traditional Forms of Financing
4/23/2009 Getting Personal: Wealthy Seek Help with Private Equity
4/15/2009 The Grapevine: New Hires at Paul Capital
4/14/2009 Squeeze Play: Private Equity Pundit
4/1/2009 Orthovita Submits Additional Data to FDA in Support of its 510(k) Application for the Use of CORTOSS® Bone Augmentation Material in Vertebral Augmentation
3/25/2009 Day of Reckoning
3/7/2009 Recession Brings Opportunities in Private Equity
2/23/2009 Mid Market Funds Find Favor
2/1/2009 Stream Power
1/22/2009 Banking's Private Equity Dilemma
1/12/2009 Secondary PE Player Eyes Regional Spree
1/8/2009 Prism Pharmaceuticals to Receive $10 Million Milestone Payment from Paul Capital Healthcare
1/5/2009 Prism Pharmaceuticals Receives FDA Approval of NEXTERONE® for Life-Threatening Ventricular Fibrillation and Ventricular Tachycardia

© 2010 by Paul Capital. All rights reserved.